From Concept to IND: In Vivo CAR-T Efficacy Supported by PharmaLegacy
August 19, 2026 /In vivo CAR-T is reshaping cell therapy — but how do you evaluate vector targeting, CAR-T kinetics, antitumor efficacy, and CRS safety within a single humanized mouse model? PharmaLegacy, as one of China's earliest preclinical CROs, combines leading humanized mouse models with deep in vivo CAR-T expertise to offer a one-stop service — from proof-of-concept to IND. The following sections detail our approach. 1. How Is In Vivo CAR-T Disrupting Traditional Therapies? Advances in vector technology and gene editing are rapidly moving in vivo CAR-T from concept to clinic. By reprogramming T cells directly inside the body, this approach bypasses the complexity of ex [...]
From Discovery to IND: Reliable Bone Metastasis Models for Your Oncology Pipeline
August 12, 2026 /Advances in organ repair, tissue repair and tissue engineering have revolutionized the way experimental orthopedics is looked at. The ability to manufacture cocktails of stem cells, biologics, and small molecules joined through biocompatible scaffolds is now being regularly used to restore both structure and function of damaged ligaments, tendons, teeth, bone, cartilage, facet joints and intervertebral discs. The relevance of developing bone and orthopedics compounds stems from their usability in both trauma (patients recovering from MVAs, etc.) and medical (spinal osteoarthritis, osteoporosis, etc.) patients. Creating novel bone and orthopedics models needs no justification in a world where new pathologies are constantly appearing and even evolving, especially when a large number of cancers metastasize to the bones. Be it melanomas, breast cancer, or colon cancer, once a tumor finds its way to a patient’s bones, survival rates drop dramatically. More than 100,000 cases of bone metastasis are diagnosed every year, [...]
Bridging the Translational Gap: How Tumor Drug-Resistance Models Bring Preclinical Research Closer to the Clinic
August 11, 2026 /Tumor drug resistance remains the leading cause of cancer treatment failure. It is estimated that over 90% of cancer-related deaths can be attributed to resistance. Whether with conventional radio- or chemo-therapy, targeted therapy, or immunotherapy, tumour cells eventually develop Acquired Resistance after prolonged drug exposure, resulting in therapeutic insufficiency, relapse, and even metastasis. Moreover, some patients show no response to anticancer treatment from the very beginning – a condition known as Intrinsic (or de novo) Resistance. Nature 575, 299–309 (2019). Biological determinants of drug resistance. Molecular mechanisms underlying drug resistance are complex and multifactorial, involving tumor heterogeneity, tumor microenvironment (TME), adaptive changes developed in growth [...]
Evaluating Weight-Loss Drug Efficacy: How to Choose the Right Animal Model?
July 28, 2026 /Since 2025, the weight-loss drug sector has entered a phase of rapid growth. The successive market approvals of Novo Nordisk's oral semaglutide (Wegovy®) and Eli Lilly's small-molecule orforglipron (Foundayo®) have marked a new era of oral administration for obesity treatment. The current pipeline of weight-loss therapeutics in development is highly diverse, spanning various molecular formats—such as peptides and small molecules—and targeting single-target GLP-1R, multi-target GLP-1R/GIPR/GCGR, as well as the amylin receptor (AMYR), among others. For a weight-loss drug to successfully advance to clinical trials, selecting a suitable preclinical animal model is just as critical as optimizing its molecular structure and target [...]
All You Need To Know About Animal Models of Wet Age-Related Macular Degeneration
January 18, 2026 /Age-related macular degeneration (AMD), a leading cause of vision loss in older adults, casts a long shadow over millions of lives worldwide. Wet AMD, a subtype characterized by abnormal blood vessel growth beneath the retina, presents a particularly treacherous threat, stealing central vision with chilling swiftness. While treatments exist, they require frequent injections and don't address the root cause of the disease. Apart from antibody drugs with intravitreal injection already in the market, other modalities and dosing routes are increasingly being tested in preclinical and clinical stage to replace or supplement current treatment. This new trend requires careful selection and [...]
Application of B Cell Depletion Therapy in Autoimmune Diseases Part III: The Relationship Between Dosage and Efficacy
November 20, 2025 /B Cell Depletion Therapy (BCDT) directly targets the root cause of immune dysregulation, restoring immune homeostasis through precise intervention, thereby emerging as a revolutionary approach for autoimmune diseases. Since most BCDT agents originate from oncology applications, while autoimmune diseases and malignancies differ significantly in therapeutic objectives and mechanisms, the complex interplay among dosage, efficacy, and side effects remains a critical research focus. Recent findings presented at the December 2024 ACR Conference highlight the substantial impact of these differences on the correlation between B cell depletion depth and clinical outcomes. In previous two articles, we explored the fundamental principles and applications of BCDT in autoimmune diseases, [...]